In response to “Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low grade glioma”

Excerpt

We read with interest the report from Genc et al. entitled “Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low grade glioma” which confirms the high frequency of this treatment related side effect (40%). The pattern of onset and severity of this reaction appears to be similar to what was observed in the pediatric low-grade glioma patients in the Canadian series [1]. The authors describe their experience of carboplatin reintroduction and desensitization with a several step process leading to successful reexposure to carboplatin in spite of persisting reactions following initial modifications of the administration protocol. Some of their patients were rechallenged after two reactions despite preventive measures. …